Cargando…
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and other benefits of GLP-1RAs, their uptake was initially limited by the fact that they could only be administered by injection. Semagluti...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515042/ https://www.ncbi.nlm.nih.gov/pubmed/35838946 http://dx.doi.org/10.1007/s11154-022-09735-8 |